Strategic Acquisition The recent acquisition of AiCuris by Asahi Kasei Group for nearly €780 million indicates strong industry confidence and potential for accelerated market expansion, presenting an opportunity to leverage increased resources and global reach.

Innovative Pipeline AiCuris is advancing its pipeline with promising candidates like Pritelivir for recurrent HSV infections and AIC468 for BK virus, creating opportunities for partnerships and sales in niche antiviral and immunocompromised patient segments.

Targeted Market Focus With flagship product PREVYMIS already marketed to transplant recipients, there is a clear pathway to expand sales within healthcare providers focusing on immunocompromised populations requiring infection management solutions.

Research & Data Leadership Active participation in major industry events and presentation of new clinical data demonstrate AiCuris' commitment to scientific leadership, providing avenues to connect with key opinion leaders and healthcare decision-makers.

Funding and Growth With $75 million in funding and recent milestone payments, AiCuris is positioned to invest in commercial expansion, clinical trials, and strategic partnerships, creating multiple opportunities for sales engagement and market penetration.